Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers.
Compare RHHBY Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Roche Holding Ltd. (ADR)
News & Analysis: Roche Holding Ltd. (ADR)
GenMark appears to be a good fit for Roche's diagnostics business.
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.
Regeneron's REGN-COV2 is a leading candidate to treat the illness.
Roche and PTC Therapeutics will challenge Novartis and Biogen with competitive pricing for Evrysdi.
Actemra fails another clinical trial, but there are still two ongoing late-stage studies.
The performance of the very timely product category mitigates declines in the company's other businesses.
Large drugmakers are hoping to stop a looming global crisis that could be much worse than COVID-19.
There are still two ongoing studies of the drug in patients infected with the novel coronavirus.